Investor Overview

Webcast ImageWebcast
Histogenics Corp Other Corporate (Live)
04/27/17 at 2:15 p.m. ET
Histogenics Corp Other Corporate
Thursday, April 27, 2017 2:15 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Our regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Our first investigational product candidate, NeoCart®, leverages our platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee. For more information on Histogenics, please visit the company website at www.histogenics.com.
Stock Quote
HSGX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$1.69
Change (%) Stock is Up 0.06 (3.68%)
Volume18,160
Data as of 04/25/17 1:36 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
04/24/17Histogenics Corporation to Present at 5th Annual Cell & Gene Therapy Investor Day on April 27, 2017
WALTHAM, Mass., April 24, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President & CEO, will present at the Alliance for Regenerative Medicine’s 5th Annual Cell & Gene Therapy Investor Day on Thursday, April 27, 2017 at 2:15 pm ET in Boston. In addition, Mr. Gridley will participate in a panel titled "Cel... 
Printer Friendly Version
03/29/17Histogenics Corporation to Present at Needham & Company’s 16th Annual Healthcare Conference
WALTHAM, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, Chief Executive Officer of Histogenics, will be presenting a corporate overview at Needham & Company’s 16th Annual Healthcare Conference on, April 5, 2017 at 09:20 AM EDT at the Westin Grand Central Hotel in New York, NY.  This presentatio... 
Printer Friendly Version
03/16/17Histogenics Corporation Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2016
‒ NeoCart® Phase 3 Clinical Trial Enrollment on Track for Completion by End of Second Quarter of 2017 ‒ ‒ Strong Performance in all Areas of the Business in 2016 ‒ ‒ Financing Completed in the Third Quarter of 2016 Expected to Fund Company to Phase 3 Data ‒ ‒ Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT ‒ WALTHAM, Mass., March 16, 2017 (GLOBE NEWSWIRE) --  Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and co... 
Printer Friendly Version
03/09/17Histogenics Announces Publication of Biomechanical and Structural Data From Human Engineered Cartilage Testing
– Data demonstrate Histogenics’ Tissue Engineered Cartilage Constructs Exhibit Mechanical Properties Approaching Native Human Cartilage as Early as Three Weeks in Culture and Prior to Implantation –  – First Study to Use Three Mechanical Tests to Examine and Understand the Performance of Repaired Cartilage in Accordance with FDA Guidance – WALTHAM, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on deve... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
04/27/17 2:15 p.m. ET
Histogenics Corp Other Corporate
Contact Information

Histogenics Corporation
Phone: 781.547.7900
E-mail: InvestorRelations@histogenics.com

Featured Documents
View the Company Profile
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Histogenics Corp posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.